Surgery remains the cornerstone of initial treatment for granulosa cell tumors (GCTs). Postoperative cytotoxic chemotherapy has often been given in attempt to improve cure rate with bleomycin, etoposide, and cisplatin (BEP) being the most widely used postoperative treatment. However, because taxanes are active drugs in GCTs, carboplatin plus paclitaxel (PC) is also considered as a reasonable alternative. In the following article, we support the use of BEP based on (i) bleomycin and etoposide as single agents are the most efficient drugs reported in literature, (ii) carboplatin has never shown equivalence to cisplatin in GCTs, (iii) BEP is the regimen associated with the strongest level of evidence, and (iv) comparison between BEP and PC failed to demonstrate a benefit in favor of PC.